Journal article
Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: Propensity matched research network analysis
Alimentary pharmacology & therapeutics, v 55(2), pp 191-200
Jan 2022
PMID: 34904240
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Background Accurate estimates for the risk of COVID-19 in IBD, and an understanding of the impact of COVID-19 on IBD course and the risk of incident post-infectious IBD are needed. Aims To estimate the risk of COVID-19 in IBD and study its impact on IBD course and the risk of incident post-infectious IBD. Methods A retrospective propensity score matched cohort study utilising multi-institutional research network TriNetX. COVID-19 patients with and without IBD were identified to quantify the risk of COVID-19 in patients with IBD, COVID-19 outcomes in patients with IBD and the impact of COVID-19 on IBD disease course. The risk of incident post-infectious IBD in COVID-19 patients was compared to the population not infected with COVID-19 during a similar time period. Results Incidence rate ratio for COVID-19 was lower in IBD patients compared to the non-IBD population (0.79, 95% CI: 0.72-0.86). COVID-19-infected patients with IBD were at increased risk for requiring hospitalisation compared to non-IBD population (RR: 1.17, 95% CI: 1.02-1.34) with no differences in need for mechanical ventilation or mortality. Patients with IBD on steroids were at an increased risk for critical care need (RR: 2.22, 95% CI: 1.29-3.82). Up to 7% of patients with IBD infected with COVID-19 suffered an IBD flare 3-months post-infection. Risk for incident IBD post-COVID was lower than that seen in the non-COVID population (RR: 0.64, 95% CI: 0.54-0.65). Conclusion We observed no increase in risk for COVID-19 amongst patients with IBD or risk for de novo IBD after COVID-19 infection. We confirmed prior observations regarding the impact of steroid use on COVID-19 severity in patients with IBD.
Metrics
1 Record Views
Details
- Title
- Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: Propensity matched research network analysis
- Creators
- Yousaf Hadi - West Virginia UniversityParambir S. Dulai - University of California, San DiegoJustin Kupec - West Virginia UniversityNabeeha Mohy-Ud-Din - Allegheny Health NetworkVipul Jairath - Western UniversityFrancis A. Farraye - Mayo Clinic in FloridaGursimran S. Kochhar - Allegheny Health Network
- Publication Details
- Alimentary pharmacology & therapeutics, v 55(2), pp 191-200
- Publisher
- Wiley
- Number of pages
- 10
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- General Internal Medicine
- Web of Science ID
- WOS:000729731100001
- Scopus ID
- 2-s2.0-85121136095
- Other Identifier
- 991022076808904721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Gastroenterology & Hepatology
- Pharmacology & Pharmacy